Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with angiosarcoma that is locally advanced, metastatic, or unable to be removed by surgery.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients are stratified according to disease type (cutaneous angiosarcoma [scalp, breast, or soft tissue] vs visceral angiosarcoma). All patients receive oral sorafenib tosylate twice daily for 9 months in the absence of disease progression or unacceptable toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically confirmed angiosarcoma
No Kaposi sarcoma, hemangiopericytoma, or hemangioendothelioma
Measurable tumor with at least 1 measurable lesion by RECIST criteria
Tumor in a previously irradiated area must not show progression
No brain metastases or meningeal tumors (symptomatic or asymptomatic)
PATIENT CHARACTERISTICS:
WHO performance status 0-2
Life expectancy ≥ 3 months
WBC ≥ 3,000/mm³
ANC ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 9 g/dL
PT or INR and aPTT ≤ 1.5 times upper limit of normal (ULN)
Liver transaminases ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)
Total bilirubin ≤ 1.5 times ULN
Serum creatinine ≤ 1.5 times ULN
Amylase and lipase ≤ 1.5 times ULN
Not pregnant or nursing
Weight loss from pre-disease weight < 20% over the past 12 months
Able to swallow
No active or ischemic coronary artery disease
No myocardial infarction within the past 6 months
No NYHA class III-IV cardiac failure
No uncontrolled hypertension
No coagulopathy
No active uncontrolled peptic ulcer
No patients on renal dialysis
No active bacterial or fungal infection > CTCAE v3.0 grade 2
No HIV or hepatitis B or C positivity
No chronic unstable illness that could jeopardize patient safety or compliance
No other progressive or malignant tumor
No known or suspected allergy to sorafenib tosylate
No psychological, familial, social, or geographic situations that preclude clinical follow up
No patients deprived of liberty or under guardianship
No cardiac arrhythmia requiring antiarrhythmic medication (except beta-blockers or digoxin for chronic atrial fibrillation)
No epilepsy requiring antiepileptic drugs
PRIOR CONCURRENT THERAPY:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal